Disease · MONDO_0019269
ichthyosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. ichthyosis. Diseases, record MONDO_0019269. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019269
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- DOC, disorder of cornification, fish scale disease, fish skin disease, ichthyosis (disease)
- Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ISOTRETINOIN | CHEMBL547 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IMSIDOLIMAB | CHEMBL4650441 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| REPROXALAP | CHEMBL4297210 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| USTEKINUMAB | CHEMBL1201835 | Antibody | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INETAGUGENE GEPERPAVEC | CHEMBL4650243 | Gene | Unknown | USAN | 1 | 0 | 0 | Drugs and targets |
Targets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL12A | Interleukin-12 | 1 | Interleukin-12 inhibitor | Early phase 1 | https://conductscience.org/library/genes/3592 | Drugs and targets |
| IL12B | Interleukin-12 | 1 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Early phase 1 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL1RAP | IL36 receptor | 1 | IL36 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3556 | Drugs and targets |
| IL23A | Interleukin-23 | 1 | Interleukin-23 inhibitor | Early phase 1 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| IL36R | IL36 receptor | 1 | IL36 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/8808 | Drugs and targets |
| RARA | Retinoic acid receptor | 1 | Retinoic acid receptor agonist | Phase 2 | https://conductscience.org/library/genes/5914 | Drugs and targets |
| RARB | Retinoic acid receptor | 1 | Retinoic acid receptor agonist | Phase 2 | https://conductscience.org/library/genes/5915 | Drugs and targets |
| RARG | Retinoic acid receptor | 1 | Retinoic acid receptor agonist | Phase 2 | https://conductscience.org/library/genes/5916 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04154293 | A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis | Phase 2 | 34 | 2022-08-25 | Congenital Ichthyosis | ISOTRETINOIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02864082 | A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis | Phase 2 | 19 | 2021-09-02 | Congenital Ichthyosis | ISOTRETINOIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04549792 | An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses | Early phase 1 | 13 | 2025-02-12 | Ichthyosis | USTEKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02402309 | A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS) | Phase 2 | 12 | 2022-12-13 | Sjögren-Larsson Syndrome | REPROXALAP | Its record names the disease | ClinicalTrials.gov |
| NCT04697056 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis | Phase 2 | 5 | 2023-03-02 | Ichthyosis | IMSIDOLIMAB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Topical NS2 1% Dermatologic Cream vs Topical Vehicle Dermatologic: Number of Participants Experiencing a Serious Adverse Event (SAE). | 0 of 6 | 0 of 6 | 12 | NCT02402309 | Trial comparisons |
| Topical NS2 1% Dermatologic Cream vs Topical Vehicle Dermatologic: Number of Participants Experiencing an Adverse Event Leading to Discontinuation. | 0 of 6 | 0 of 6 | 12 | NCT02402309 | Trial comparisons |
| Topical NS2 1% Dermatologic Cream vs Topical Vehicle Dermatologic: deaths from any cause | 0 of 6 | 0 of 6 | 12 | NCT02402309 | Trial comparisons |
| Topical NS2 1% Dermatologic Cream vs Topical Vehicle Dermatologic: serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT02402309 | Trial comparisons |
| Imsidolimab vs Placebo: deaths from any cause | 0 of 4 | 0 of 1 | 5 | NCT04697056 | Trial comparisons |
| Imsidolimab vs Placebo: serious adverse events | 0 of 4 | 0 of 1 | 5 | NCT04697056 | Trial comparisons |
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 37170057 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019269
GET https://conductscience.org/api/diseases/v1/MONDO_0019269/drugs